Bladder cancer: Lack of progress in bladder cancer--what are the obstacles?

作者信息

Soloway Mark S

机构信息

Department of Urology, University of Miami Miller School of Medicine, PO Box 016960 (M814), Miami, FL 33103, USA.

出版信息

Nat Rev Urol. 2013 Jan;10(1):5-6. doi: 10.1038/nrurol.2012.219. Epub 2012 Nov 20.

DOI:10.1038/nrurol.2012.219

PMID:23165404

Abstract

摘要

相似文献

Bladder cancer: Lack of progress in bladder cancer--what are the obstacles?

Nat Rev Urol. 2013 Jan;10(1):5-6. doi: 10.1038/nrurol.2012.219. Epub 2012 Nov 20.

Bladder cancer in 2016: News in diagnosis, treatment, and risk group assessment.

Nat Rev Urol. 2017 Feb;14(2):74-76. doi: 10.1038/nrurol.2016.264. Epub 2017 Jan 4.

Bladder cancer in 2012: Challenging current paradigms.

Nat Rev Urol. 2013 Feb;10(2):67-8. doi: 10.1038/nrurol.2012.252. Epub 2013 Jan 8.

Bladder cancer: revealing news about a hidden threat.

Nursing. 2006 Apr;36(4):54-7. doi: 10.1097/00152193-200604000-00041.

Pioglitazone and bladder cancer: FDA's assessment.

Pharmacoepidemiol Drug Saf. 2017 Feb;26(2):117-118. doi: 10.1002/pds.4154. Epub 2017 Jan 9.

Are we making significant progress in the diagnosis and management of bladder cancer?

J Urol. 2010 May;183(5):1667-8. doi: 10.1016/j.juro.2010.02.2376. Epub 2010 Mar 17.

ICUD-EAU International Consultation on Bladder Cancer 2012: Recommendations on bladder cancer-progress in a cancer that lacks the limelight.

Eur Urol. 2013 Jan;63(1):1-3. doi: 10.1016/j.eururo.2012.07.045. Epub 2012 Jul 31.

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.

J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053. doi: 10.6004/jnccn.2018.0072.

Summaries for patients: screening for bladder cancer: recommendations from the U.S. Preventive Services Task Force.

Ann Intern Med. 2011 Aug 16;155(4):I-36. doi: 10.7326/0003-4819-155-4-201108160-00002.

Nursing care and treatment of patients with bladder cancer.

Nurs Stand. 2009;23(37):47-56; quiz 58. doi: 10.7748/ns2009.05.23.37.47.c6973.

引用本文的文献

Promoting effect and immunologic role of secretogranin II on bladder cancer progression via regulating MAPK and NF-κB pathways.

Apoptosis. 2024 Feb;29(1-2):121-141. doi: 10.1007/s10495-023-01898-2. Epub 2023 Oct 17.

Peptidase inhibitor (PI16) impairs bladder cancer metastasis by inhibiting NF-κB activation via disrupting multiple-site ubiquitination of NEMO.

Cell Mol Biol Lett. 2023 Jul 31;28(1):62. doi: 10.1186/s11658-023-00465-6.

A novel signature of aging-related genes associated with lymphatic metastasis for survival prediction in patients with bladder cancer.

Front Oncol. 2023 Jun 27;13:1140891. doi: 10.3389/fonc.2023.1140891. eCollection 2023.

Label-free LC-MS/MS proteomics analyses reveal CLIC1 as a predictive biomarker for bladder cancer staging and prognosis.

Front Oncol. 2023 Jan 16;12:1102392. doi: 10.3389/fonc.2022.1102392. eCollection 2022.

Construction of cuproptosis-related gene signature to predict the prognosis and immunotherapy efficacy of patients with bladder cancer through bioinformatics analysis and experimental validation.

Front Genet. 2022 Nov 23;13:1074981. doi: 10.3389/fgene.2022.1074981. eCollection 2022.

STIL Promotes Tumorigenesis of Bladder Cancer by Activating PI3K/AKT/mTOR Signaling Pathway and Targeting C-Myc.

Cancers (Basel). 2022 Nov 24;14(23):5777. doi: 10.3390/cancers14235777.

Repression of the PRELP gene is relieved by histone deacetylase inhibitors through acetylation of histone H2B lysine 5 in bladder cancer.

Clin Epigenetics. 2022 Nov 12;14(1):147. doi: 10.1186/s13148-022-01370-z.

Single-Cell Sequencing Reveals that DBI is the Key Gene and Potential Therapeutic Target in Quiescent Bladder Cancer Stem Cells.

Front Genet. 2022 Jun 3;13:904536. doi: 10.3389/fgene.2022.904536. eCollection 2022.

Study on Molecular Information Intelligent Diagnosis and Treatment of Bladder Cancer on Pathological Tissue Image.

Front Med (Lausanne). 2022 Jun 3;9:838182. doi: 10.3389/fmed.2022.838182. eCollection 2022.

circDHTKD1 promotes lymphatic metastasis of bladder cancer by upregulating CXCL5.

Cell Death Discov. 2022 May 3;8(1):243. doi: 10.1038/s41420-022-01037-x.

本文引用的文献

Demographic analysis of randomized controlled trials in bladder cancer.

BJU Int. 2013 Mar;111(3):419-26. doi: 10.1111/j.1464-410X.2012.11401.x. Epub 2012 Aug 29.

Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology.

Cancer. 2009 Sep 15;115(18):4096-103. doi: 10.1002/cncr.24463.

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.

Eur Urol. 2008 Aug;54(2):303-14. doi: 10.1016/j.eururo.2008.04.051. Epub 2008 Apr 30.

Cancer statistics, 2008.

CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.

Expectant management of small, recurrent, noninvasive papillary bladder tumors.

J Urol. 2003 Aug;170(2 Pt 1):438-41. doi: 10.1097/01.ju.0000076621.71247.6c.

Does cystoscopy correlate with the histology of recurrent papillary tumours of the bladder?

BJU Int. 2001 Nov;88(7):683-5. doi: 10.1046/j.1464-4096.2001.02396.x.

Superficial bladder cancer: progression and recurrence.

J Urol. 1983 Dec;130(6):1083-6. doi: 10.1016/s0022-5347(17)51695-x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr
超能文献

Bladder cancer: Lack of progress in bladder cancer--what are the obstacles?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献

Suppr超能文献

Bladder cancer: Lack of progress in bladder cancer--what are the obstacles?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献

Suppr
超能文献